BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26625737)

  • 1. Chronic Myeloid Leukemia--Prognostic Value of Mutations.
    Kaleem B; Shahab S; Ahmed N; Shamsi TS
    Asian Pac J Cancer Prev; 2015; 16(17):7415-23. PubMed ID: 26625737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
    Huang R; Kang Q; Liu H; Li Y
    Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of BCR-ABL gene mutations in chronic myeloid leukemia using biochips].
    Ikonnikova AY; Yatsenko YE; Kremenetskaya OS; Vinogradova OV; Fesenko DO; Abramov IS; Ovsepyan VA; Nasedkina TV
    Mol Biol (Mosk); 2016; 50(3):474-9. PubMed ID: 27414785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations Associated with Imatinib Mesylate Resistance - Review.
    Linev AJ; Ivanov HJ; Zhelyazkov IG; Ivanova H; Goranova-Marinova VS; Stoyanova VK
    Folia Med (Plovdiv); 2018 Dec; 60(4):617-623. PubMed ID: 31188765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.
    Rostami G; Hamid M; Yaran M; Khani M; Karimipoor M
    J Hum Genet; 2015 May; 60(5):253-8. PubMed ID: 25740611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
    Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
    Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
    Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
    Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.